These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 38272563)
41. [A clinicopathological and immunohistochemical study of 34 cases of chordoma]. Hu Y; Gao Y; Zhang X Zhonghua Bing Li Xue Za Zhi; 1996 Jun; 25(3):142-4. PubMed ID: 9275666 [TBL] [Abstract][Full Text] [Related]
42. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. Shalaby A; Presneau N; Ye H; Halai D; Berisha F; Idowu B; Leithner A; Liegl B; Briggs TR; Bacsi K; Kindblom LG; Athanasou N; Amary MF; Hogendoorn PC; Tirabosco R; Flanagan AM J Pathol; 2011 Feb; 223(3):336-46. PubMed ID: 21171079 [TBL] [Abstract][Full Text] [Related]
43. Differences in stromal component of chordoma are associated with contrast enhancement in MRI and differential gene expression in RNA sequencing. Park M; Park I; Hong CK; Kim SH; Cha YJ Sci Rep; 2022 Oct; 12(1):16504. PubMed ID: 36192442 [TBL] [Abstract][Full Text] [Related]
44. Chordoma and chondroid neoplasms of the spheno-occiput. An immunohistochemical study of 41 cases with prognostic and nosologic implications. Mitchell A; Scheithauer BW; Unni KK; Forsyth PJ; Wold LE; McGivney DJ Cancer; 1993 Nov; 72(10):2943-9. PubMed ID: 7693324 [TBL] [Abstract][Full Text] [Related]
45. Loss of SMARCB1/INI1 expression in poorly differentiated chordomas. Mobley BC; McKenney JK; Bangs CD; Callahan K; Yeom KW; Schneppenheim R; Hayden MG; Cherry AM; Gokden M; Edwards MS; Fisher PG; Vogel H Acta Neuropathol; 2010 Dec; 120(6):745-53. PubMed ID: 21057957 [TBL] [Abstract][Full Text] [Related]
46. Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1. Rinner B; Froehlich EV; Buerger K; Knausz H; Lohberger B; Scheipl S; Fischer C; Leithner A; Guelly C; Trajanoski S; Szuhai K; Liegl B Int J Oncol; 2012 Feb; 40(2):443-51. PubMed ID: 22002331 [TBL] [Abstract][Full Text] [Related]
47. Comparative analysis of histopathological parameters, genome-wide copy number alterations, and variants in genes involved in cell cycle regulation in chordomas of the skull base and sacrum. Salle H; Durand S; Durand K; Bourthoumieu S; Lemnos L; Robert S; Pollet J; Passeri T; Khalil W; Froelich S; Adle-Biassette H; Labrousse F J Neuropathol Exp Neurol; 2023 Mar; 82(4):312-323. PubMed ID: 36779322 [TBL] [Abstract][Full Text] [Related]
48. Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma. Morimoto Y; Tamura R; Ohara K; Kosugi K; Oishi Y; Kuranari Y; Yoshida K; Toda M J Neurooncol; 2019 Aug; 144(1):65-77. PubMed ID: 31240525 [TBL] [Abstract][Full Text] [Related]
49. The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies. Xu J; Shi Q; Wang B; Ji T; Guo W; Ren T; Tang X Front Immunol; 2023; 14():1257254. PubMed ID: 37720221 [TBL] [Abstract][Full Text] [Related]
51. Prognostic value of MIB-1, p53, epidermal growth factor receptor, and INI1 in childhood chordomas. Yadav R; Sharma MC; Malgulwar PB; Pathak P; Sigamani E; Suri V; Sarkar C; Kumar A; Singh M; Sharma BS; Garg A; Bakhshi S; Faruq M Neuro Oncol; 2014 Mar; 16(3):372-81. PubMed ID: 24305715 [TBL] [Abstract][Full Text] [Related]
52. Clinical and histopathologic features of chordomas in children and young adults. Ridenour RV; Ahrens WA; Folpe AL; Miller DV Pediatr Dev Pathol; 2010; 13(1):9-17. PubMed ID: 19348512 [TBL] [Abstract][Full Text] [Related]
54. Immune Landscape of Invasive Ductal Carcinoma Tumor Microenvironment Identifies a Prognostic and Immunotherapeutically Relevant Gene Signature. Bao X; Shi R; Zhang K; Xin S; Li X; Zhao Y; Wang Y Front Oncol; 2019; 9():903. PubMed ID: 31620363 [No Abstract] [Full Text] [Related]
55. Discovery of a glucocorticoid receptor (GR) activity signature correlates with immune cell infiltration in adrenocortical carcinoma. Wu K; Liu Z; Liang J; Zhu Y; Wang X; Li X J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793855 [TBL] [Abstract][Full Text] [Related]
56. Chondroid chordoma--a variant of chordoma. A morphologic and immunohistochemical study. Rosenberg AE; Brown GA; Bhan AK; Lee JM Am J Clin Pathol; 1994 Jan; 101(1):36-41. PubMed ID: 7506477 [TBL] [Abstract][Full Text] [Related]
57. Expression of E-cadherin in chordomas: diagnostic marker and possible role of tumor cell affinity. Mori K; Chano T; Kushima R; Hukuda S; Okabe H Virchows Arch; 2002 Feb; 440(2):123-127. PubMed ID: 11964040 [TBL] [Abstract][Full Text] [Related]
58. Clinicopathological and Prognostic Characteristics in Extra-Axial Chordomas: An Integrative Analysis of 86 Cases and Comparison With Axial Chordomas. Lv GH; Zou MX; Liu FS; Zhang Y; Huang W; Ye A; Zhang QS; Wang XB; Li J; Jiang Y; She XL Neurosurgery; 2019 Sep; 85(3):E527-E542. PubMed ID: 30892619 [TBL] [Abstract][Full Text] [Related]
60. Overexpression of the BMP4/SMAD signaling pathway in skull base chordomas is associated with poor prognosis. Feng Y; Zhang Q; Wang Z; Yan B; Wei W; Li P Int J Clin Exp Pathol; 2015; 8(7):8268-75. PubMed ID: 26339396 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]